Curated News
By: NewsRamp Editorial Staff
October 22, 2026
Datavault AI to Acquire 19.9% Stake in DataMEDS via License Expansion
TLDR
- Datavault AI gains a 19.9% stake in DataMEDS and potential royalties while retaining its intellectual property.
- Datavault AI expands its technology license with DataMEDS, which assumes commercialization costs and integrates Datavault AI Health technologies.
- The deal aims to advance patient-controlled health data access and monetization across pharmacies, labs, and wearables.
- Datavault AI would designate one director to the DataMEDS board and targets a fourth-quarter 2026 closing.
Impact - Why it Matters
This proposed deal signals a growing trend of AI and blockchain convergence in healthcare, where patient-controlled data and tokenization could revolutionize how medical information is managed and monetized. For investors, it offers Datavault AI a royalty stream without heavy commercialization costs, while DataMEDS gains access to advanced data technologies. If completed, the partnership could accelerate the adoption of secure, patient-centric health data platforms, impacting how individuals control their health information and how companies innovate in the digital health space. The collaboration also highlights the increasing value of intellectual property licensing in the AI era, potentially setting a precedent for similar deals.
Summary
Datavault AI (NASDAQ: DVLT) has announced a nonbinding letter of intent to acquire a 19.9% equity stake in DataMEDS AI Inc. (NASDAQ: MEDS) by expanding their existing technology license. The deal would allow Datavault AI to retain ownership of its intellectual property while earning royalty revenue from commercialization, with DataMEDS bearing the costs. Datavault AI would also have the right to appoint one director to DataMEDS’ board after closing. The companies aim for a fourth-quarter 2026 closing, pending due diligence and definitive agreements.
The expanded license would integrate Datavault AI Health technologies into DataMEDS’ PharmacyChain platform and EinsteinRx AI capabilities, enabling patient-controlled health data access, management, monetization, and tokenization across pharmacy, laboratory, wearable, and other healthcare environments. This initiative aligns with DataMEDS’ broader strategy to enhance its healthcare technology through partnerships with EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors, and REBOOT Health AI. The letter of intent is nonbinding and does not guarantee completion. For full details, visit https://ibn.fm/Q8IGK.
Datavault AI, headquartered in Philadelphia, is a leader in AI-driven data experiences and monetization for Web 3.0, with divisions in Acoustic Sciences and Data Sciences. Its technologies serve multiple industries, including healthcare, and its Information Data Exchange enables Digital Twins and NIL licensing. The company’s platform offers customizable AI and machine-learning automation, analytics, and advertising monitoring. This proposed transaction underscores Datavault AI’s commitment to expanding its healthcare footprint and generating new revenue streams.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Datavault AI to Acquire 19.9% Stake in DataMEDS via License Expansion
